Articles related to BREAST CANCER

Reevaluation of major hormone therapy studies has prompted renewed discussion about menopause treatment in breast cancer survivors. Emerging interpretation of older trial data suggests treatment risks may vary by patient characteristics and hormone formulation rather than applying uniformly across all populations.

Low-dose (Z)-endoxifen significantly reduced mammographic breast density in premenopausal women while producing fewer treatment-related symptoms than expected with standard tamoxifen exposure. The phase II findings suggest a potential new prevention strategy, but effects on actual breast cancer incidence remain unknown.

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

Nearly 18 million US women aged 45–64 were overdue for at least one recommended breast, cervical, or colorectal cancer screening, with colorectal cancer representing the largest unmet need in a 2024 BRFSS analysis of 36.2 million women.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.